How Wall Street’s ‘fear gauge’ is being rigged,

New Post Public Reply Private Reply Replies (0) Message Board
AlanC AlanC #88327
364
How Wall Street’s ‘fear gauge’ is being rigged, according to one whistleblower
By Mark DeCambre, Francine McKenna
Published: Feb 14, 2018 7:34 am ET
Cboe says whistleblower letter is filled with ‘inaccurate statements’
Cboe’s VIX products is the target of a whistleblower
Cboe’s VIX products is the target of a whistleblower
One of the most popular measures of volatility is being manipulated, charges one individual who submitted a letter anonymously to the Securities and Exchange Commission and the Commodity Futures Trading Commission.

The letter makes the claim to regulators that fake quotes for the S&P 500 index SPX+0.26% are skewing levels of the Cboe Volatility Index VIX-8.01% which reflects bearish and bullish options bets 30-days in the future on the S&P 500 to gauge implied stock-market volatility (see excerpt from the letter below).


The flaw allows trading firms with sophisticated algorithms to move the VIX up or down by simply posting quotes on S&P options and without needing to physically engage in any trading or deploying any capital. This market manipulation has led to multiple billions in profits effectively taken away from institutional and retail investors and cashed in by unethical electronic option market makers.

The whistleblower’s claims are consistent with those documented by John Griffin, professor of finance at the University of Texas and Ph.D. candidate Amin Shams in May 2017 in research that says the cost of manipulating less-liquid SPX options would be more than paid for by a successful bet on the direction of the VIX. The paper is consistent with the whistleblower’s conclusion—that manipulators are moving prices of the SPX options by spoofing at settlement—entering quotes for trades that are never executed—to “paint the tape” and, therefore, influence the value of expiring VIX derivatives.

Opinion: How S&P 500 options may be used to manipulate VIX ‘fear gauge’

The VIX has underpinned a number of strategies described as so-called short-volatility, which imploded dramatically last Monday when VIX, also known as Wall Street’s fear gauge, registered its largest percentage change in its history, cratering bets that volatility measures would fall, if not remain muted.

Short volatility products, notably, VelocityShares Daily Inverse VIX Short Term ETN XIV-0.75% tumbled 90% in after-hours trade Feb. 5 as the Dow Jones Industrial Averaged DJIA+0.16% plunged 1,175 points, or 4.6%, marking its sharpest point drop in the blue-chip gauge’s 121-year history. Another product, the exchange-traded fund ProShares Short VIX Short-Term Futures ETF SVXY-0.44% known by its ticker SVXY, also tanked last week.


Credit Suisse, the sponsor, of VelocityShares Daily, or XIV, said it planned to liquidate the product on Feb. 21.

The spectacularly wrongway short bets had become one of the most popular trades on Wall Street because volatility had gone eerily absent for a protracted period, encouraging investors, who were lamenting the narrow trading ranges present during that period of placidity, to make more aggressive wagers to generate richer returns. Those moves also came amid ultralow rates for government bonds, particularly the 10-year Treasury note BX:TMUBMUSD10Y-0.35%

Jason Zuckerman, attorney at law firm, Zuckerman Law, who is representing the anonymous whistleblower, told MarketWatch that his client is concerned about unfair markets.

“My client is concerned about VIX manipulation that has already caused investors to incur massive losses and is eager to prevent further harm from investors,” Zuckerman said.

The whistleblower would also like the market regulates to play a more active role in preventing further harm to investors including requiring more accurate and comprehensive disclosures about the various risks that are associated with products linked to VIX,” he said.


The letter urges “the SEC and CFTC to promptly investigate the matter before investors suffer additional losses due to this fraud.”

Zuckerman’s whistleblower further charges that the average retail investor isn’t aware of how exchange-traded products like XIV are rebalanced daily and that a “mismatch” in the nature of short-volatility products means “a larger move in spot-volatility in either direction requires excessive buying or selling pressure whenever short volatility assets are dominant.”


One error that market participants have pointed out is that Zuckerman and his client in the letter refer to the CME Group Inc., at one point rather than the Cboe Global Markets Inc., which oversees the VIX product.

“This letter is replete with inaccurate statements, misconceptions and factual errors, including a fundamental misunderstanding of the relationship between the VIX Index, VIX futures and volatility exchange traded products, among other things,” a Cboe spokeswoman said in a statement.

Messages to the SEC and the CFTC weren’t immediately returned.

The whistleblower claim also comes amid heightened regulatory scrutiny around short-VIX products, including former CFTC Commissioner Bart Chilton, who told MarketWatch that warnings about products like XIV should be written in “big, bold 24-point font and in red letters.”

A CBOE press release said that Feb. 5-Feb. 9 was the busiest week in the exchange’s history with a record weekly high of 48.29 million contracts traded. However, shares of CBOE, which merged with merged with Bats Global Markets last year, lost 20% last week when after the market mayhem cast doubt on whether these products would remain viable choices for traders.

CBOE executives are confident its VIX product will continue to do well in all market conditions. On its earnings call, John Deters, CBOE’s chief strategy officer, told analysts, “It’s really an exceptional event when the level of VIX increases and doubles in a matter of just a handful of days. That’s occurred, and now we’re at a point where — and professionals know this — we’re at a point where the short VIX strategy tends to work quite well.”

CBOE Chairman and CEO Edward Tilly refuted concerns about the impact of the problems at some exchange-traded products and added that the exchange saw record trading volume in VIX futures and options in 2017. “The activity we see from issuers of XIV and SVXY is less than 5% of all VIX futures trading, representing average daily volume of about 12,000 contracts,” Trilly said. Non-institutional holders of these ETPs were approximately 21% of total holdings in the last reported period, he said, with the remainder consisting of “sophisticated institutional users who employ inverse VIX ETPs as part of a diverse mix of trading and investing strategies.”

Original post by Here today!

Nanotech Entertainment Inc. (NTEK) Stock Research Links

NTEK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

eGlint's Rapid Tech Revolutionizes Proteomics with Win

Updated Category News Views 5

A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...

Continue Reading
Richard Huffman Joins IFA Board, Strengthens Franchise Ties

Updated Category News Views 17

Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...

Continue Reading
Plata Hits $1 Billion ARR in Record Digital Bank Growth

Updated Category News Views 10

Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...

Continue Reading
Ruth E. Carter Returns Home with Celebrated Exhibition

Updated Category News Views 7

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

Continue Reading
Navigating the Nitty-Gritty of Cabin Rental Management

Updated Category News Views 5

The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...

Continue Reading
2GenPen & LordCap Team Up: Game-Changer in ABS?

Updated Category News Views 8

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Continue Reading
LBT Unveils Game-Changing Cyclotron for Medical Advances

Updated Category News Views 8

Unveiling the LB-30 Cyclotron at EANM 2026 Life in nuclear medicine never stands still, and once again, Longevous Beamtech (LBT) is stirring the pot with its brand-new LB-30 series medical cyclotron. They rolled out this high-powered beast at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna. Leaning into the 30 MeV energy...

Continue Reading
CMS Proposal Sparks Controversy in Lab Certification

Updated Category News Views 5

A New Contender in the Battle Over Lab Standards Here's what’s heating up in the realm of clinical laboratories: A proposed shift by the Centers for Medicare & Medicaid Services (CMS) that reeks of cutting corners, if you ask the folks at the Association for Diagnostics & Laboratory Medicine (ADLM). They’re banging the drums against CMS's idea to nix the board...

Continue Reading
Noé Hinojosa Jr. Honored for Leadership in Business

Updated Category News Views 6

From Bonds to Ballgames: Hinojosa's Impact Listen up, because this one’s more than just another accolade on a shelf. Noé Hinojosa Jr., a big gun over at TRB Securities, is getting the 2026 Hispanic Business Salute Award, and it's a doozy. Awarded by all the big wigs—UPS, NBC 5, Telemundo 39, and the Dallas Cowboys—this isn't a small pat on the back. It's a full-on...

Continue Reading
Clean Power Alliance's Bond Deal Secures $91M Savings

Updated Category News Views 9

CPA Triumphs Yet Again With Bond Savings I'll tell you, the Clean Power Alliance (CPA) just hit the jackpot again. We're talking a $1.4 billion energy prepayment bond deal that locks in a whopping $91.1 million in savings over the next seven years. Not bad, huh? A Closer Look at the Numbers CPA's charm—besides being the top green power supplier in the U.S.—is spinning...

Continue Reading

Top 5 Most Recently Viewed Articles

Freeport-McMoRan Faces Class Action Amidst Safety Allegations

Updated Category News Views 160

Understanding the Class Action Against Freeport-McMoRan Recently, a prominent securities law firm announced a class action lawsuit against Freeport-McMoRan Inc. (NYSE: FCX), targeting potential securities fraud as stock prices drastically fell. This lawsuit follows serious allegations concerning the company's safety practices that may have played a part in significant...

Continue Reading
GRAIL Faces Lawsuit: Opportunity for Shareholder Action

Updated Category News Views 10

A Shaky Stage in GRAIL's Financial Play When you look at company dramas, GRAIL's latest saga is nothing short of a plot twist worthy of Wall Street headlines. The firm's recent misadventures have landed them in hot water—a securities fraud lawsuit. Investors, if you had a stake in this during the class period, it’s time to wake up and smell the potential losses....

Continue Reading
Breathe Drops: A Game-Changer for Respiratory Wellness

Updated Category News Views 294

Introducing Breathe Drops: A Revolutionary Wellness Solution In the ever-evolving world of wellness, Breathe is thrilled to unveil its latest product, Breathe Drops. This unique formula aims to enhance lung health and respiratory wellness by harnessing the power of carefully selected natural ingredients. Designed for individuals seeking natural wellness solutions, Breathe...

Continue Reading
aTyr Pharma Faces Class Action After Phase 3 Trial Setbacks

Updated Category News Views 180

Introduction to aTyr Pharma Inc. aTyr Pharma Inc. (NASDAQ: ATYR) is a biopharmaceutical company focused on developing therapies for serious diseases. The company’s innovative approach strives to improve patient outcomes through its protein therapeutics. Recent Developments In late 2025, aTyr Pharma faced a significant setback when it announced that its Phase 3 study for...

Continue Reading
Crucial Steps for EPSO-G's Upcoming Extraordinary Meeting

Updated Category News Views 65

Understanding EPSO-G's Extraordinary General Meeting EPSO-G, a key player in the energy sector, has taken an important step by convening an Extraordinary General Meeting (EGM). This decision was initiated by the Board of Energy Transmission and Exchange Group EPSO-G, representing a significant moment for the organization and its stakeholders. Purpose of the Meeting The...

Continue Reading